RecruitingNCT04439708
Rare condition
Central serous chorioretinopathy
4
studies recruiting now
as of 7 Sept 2026
89
studies registered in total
as of 7 Sept 2026
4
countries with a recruiting site
as of 7 Sept 2026
30 Jul 2024
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNot applicableNCT06527326
the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy
RecruitingNCT06346405
Central Serous Chorioretinopathy and Micropulse Laser Treatment
RecruitingNCT02141308
OCT in Rare Chorioretinal Diseases
Showing the 4 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Central serous chorioretinopathy studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Central serous chorioretinopathy study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Central serous chorioretinopathy
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
11 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 2/3Bevacizumab (Abevmy)
Phase 2Eplerenone (Eplerenone)
Phase 2Mifepristone (Korlym)
Phase 2Brinzolamide (Azopt)
Phase 2Methotrexate (Ebetrex)
Phase 2Aflibercept (Eylea)
Phase 1/2Omeprazole (Antra)
Phase 1/2Metronidazole (Acea)
+ 3 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).